This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Pharmaceutical Ethic Codes: How to draft a Pharmaceutical Ethic Codes without inhibiting your business

Abstract

Pharmaceutical Industry is very risky business, not only that the company needs to grow its profit but it must show to the people that they contribute to the human health without taking any advantage from the people illness and also making sure that the medicines will not having any bad side effect to the human body. So, for running its business the Pharmaceutical Company should establish Compliance & Ethic Code Program to make sure that the Production Department must maintain the Good Manufacturing Practices and the Sales Department shall always convince the physician to prescribe the products without breaching any medical ethic. But sometimes the Compliance and Ethic Code Program are inhibiting the pharmaceuticals business growth because some of the clauses prohibit some actions while in some areas it is a common business practices. For example, some countries prohibit commercial advertising in television or public newspaper for Ethical Products. In connection with above-mentioned purposes, it’s an In-house legal counsel duty to maintain the Compliance and Ethic Code Program and compromise with the business practices at the same time. It’s our jobs to determine that the corporate actions by employees should be complying with the prevailing laws and regulation. I want to bring up a phrase “To be idealist is good choice but to be compromise it’s a better choice”, it means that in order to survive in the Pharmaceutical Company, in-house legal should be in the position of compromise status. So when we draft a Compliance and Ethic Code, we must make sure that the draft still comply with local regulation and at same times its not eliminate the ability of the Pharmaceutical Company and its employees in competing with its competitors.

Author

Portrait image of Tri Junanto Wicaksono
Tri Junanto Wicaksono
Head of GA & Legal, PT. Amerta Indah Otsuka, Indonesia

Tri Junanto Wicaksono, born in Balikpapan – Indonesia in 1977, Bachelor of International Law from University of Pancasila, Indonesia in 1999 and Master of Business Law from University of Pelita Harapan, Indonesia in 2004. He’s been working in multinational company from the year of 2000. His first company is PT. KGD Indonesia (Automotive Spare part Manufacture) with HONDA as the majority shareholders from 2000 – 2003, second company is PT. Indonesia Nippon Seiki (Automotive Speedometer Manufacture) from 2003 – 2005, third company is PT. Takeda Indonesia (Pharmaceutical Manufacture) from 2005 – 2009, the fourth and current company is PT. Amerta Indah Otsuka (Nutraceuticals [Nutrition + Pharmaceutical] Manufacture) which a subsidiary company of Otsuka Pharmaceutical Co. Ltd. from 2009 until now as Head of GA & Legal and also Compliance Officer.

Company

PT. Amerta Indah Otsuka

PT. Amerta Indah Otsuka is a subsidiary company of Otsuka Pharmaceutical Co. Ltd. Japan, a famous Pharmaceutical company from Japan. Otsuka Group main operations are: Pharmaceutical Business, Nutraceuticals (Nutrition + Pharmaceutical) Business, Consumer Products Business and Other Busines. PT. Amerta Indah Otsuka (AIO) is in Nutraceuticals Business which operating in Indonesia. AIO manufactures and markets nutraceutical products that support the maintenance and enhancement of day-to-day wellness. The products of AIO are: POCARI SWEAT, an electrolytes supply drink and SOYJOY, a healthy fruit soy bar. You can find out more about Otsuka Group in www.otsuka.com/en or about AIO and its products in www.aio.co.id, www.pocarisweat.co.id, www.soyjoy.co.id

Related Papers

The new EFPIA Disclosure Code – Is the Need for Transparency Outweighing Data Privacy Compliance?
European Federation of Pharmaceutical Industries and Associations (EFPIA) adopted on 24 June 2013, the EFPIA Disclosure Code, that is a code of conduct which obliges its member companies, from 2016,...Read more
Portrait image of John Giannakakis
John Giannakakis
Regional Counsel Southern Europe , G4s Rms , Greece
Corporate Conglomerates: Advantages, Disadvantages, Successes and Failures, Including Case Studies of General Electric and Berkshire Hathaway
This article discusses the rise and fall of corporate structures commonly referred to as “conglomerates.” They represent a collection of different companies, either in distinct industries or concentrated in one...Read more
Portrait image of Bruce Ortwine
Bruce Ortwine
General Counsel (retired), Americas; Adviser, Global Legal and Compliance (Retired), Sumitomo Mitsui Trust Bank, Limited and Sumitomo Mitsui Trust Holdings, Inc., USA
Patent Strategies for Attenuated Pathogen Vaccines
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
Portrait image of David Dolberg
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA
Ways to Avoid Having your Patents Cellected*
The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more
Portrait image of Tom Irving
Tom Irving
Partner, Marbury Law Group, USA
Portrait image of Xiaoguang Michelle Gao
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel , Eli Lilly and Company, USA
Portrait image of Michelle E. O'Brien
Michelle E. O'Brien
Partner, Marbury Law Group, USA